Chirag K. Patel - 10 Aug 2026 Form 4 Insider Report for Amneal Pharmaceuticals, Inc. (AMRX)

Reporting relationship: President & Co-CEO, Director
Issuer ticker: AMRX
Reported as of: 10 Aug 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 12 Aug 2026, 16:37:56 UTC
Prior SEC filing: 05 Mar 2026
Source filing: View source filing
Reporting owner signature: /s/ Denis Butkovic, Attorney-in-Fact

Key filing fact

Chirag K. Patel filed Form 4 for Amneal Pharmaceuticals, Inc. (AMRX) on 12 Aug 2026.

Key facts

This page summarizes Chirag K. Patel's Form 4 filing for Amneal Pharmaceuticals, Inc. (AMRX).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 12 Aug 2026, 16:37.

Change

Previous filing in this sequence was filed on 05 Mar 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001738701 Primary reporting owner

Patel Chirag K.

Relationship: President & Co-CEO, Director
Address: C/O AMNEAL PHARMACEUTICALS, INC., 400 CROSSING BOULEVARD, BRIDGEWATER
Signature: /s/ Denis Butkovic, Attorney-in-Fact
Signature date: 12 Aug 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

AMRX transaction

Class A Common Stock

Award

Transaction value
Shares: +6,381,734
Change %
Price
Shares after: 6,381,734
Date: 10 Aug 2026
Ownership: By Limited Liability Companies
Footnotes: F1

AMRX holding

Class A Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 1,393,470
Date: 10 Aug 2026
Ownership: Direct

AMRX holding

Class A Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 21,269,420
Date: 10 Aug 2026
Ownership: By Family Trusts

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

On August 10, 2026, pursuant to a Membership Interest Purchase Agreement, dated as of April 21, 2026 (as amended from time to time, the Purchase Agreement), by and among the Issuer, Kashiv BioSciences, LLC (Kashiv), KB Seller Representative, LLC and the equity holders of Kashiv named therein (the Sellers), a subsidiary of the Issuer purchased (the Acquisition) from the Sellers 100% of the issued and outstanding membership interests of Kashiv for an aggregate consideration of $375,000,000 in cash, subject to certain purchase price adjustments, and 28,942,098 shares of Issuer Class A common stock (Class A Common Stock). Pursuant to the terms of the Purchase Agreement, limited liability companies managed by the Reporting Person received 6,381,734 shares of Class A Common Stock in the Acquisition.